Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 12/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23902189 | 0.86 | NISCH (0.49) | NISCHMAOB | |
| SCHEMBL23565994 | 0.79 | NISCH (0.56) | NISCHMAOBPTGIR | |
| SCHEMBL23902237 | 0.79 | NISCH (0.51) | NISCHMAOBPTGIRKDM4E | |
| SCHEMBL23901878 | 0.77 | NISCH (0.46) | NISCHMAOBPTGIRKDM4E | |
| SCHEMBL23902325 | 0.77 | NISCH (0.49) | NISCHMAOBPTGIRKDM4E | |
| SCHEMBL13175784 | 0.75 | NISCH (0.60) | NISCHMAOBPTGIRKDM4E | |
| SCHEMBL9575182 | 0.74 | MAOB (0.69) | NISCHMAOBPTGIRKDM4E | |
| SCHEMBL23901886 | 0.73 | NISCH (0.48) | NISCHMAOBPTGIR | |
| SCHEMBL23901784 | 0.73 | NISCH (0.49) | NISCHMAOBKDM4E | |
| SCHEMBL23902260 | 0.72 | NISCH (0.60) | NISCHMAOBPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | NISCH 24/4885MAOB 2311/4885GFER 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.